BiSKITs represent our novel platform comprised of Bifunctional SuperKine ImmunoTherapies
One Molecule, Two Functions, Infinite Possibilities
The versatility of our Superkine platform facilitates use of fusion technology to amplify the capabilities of our naked IL-2, IL-4 and IL-13 Superkines which were originally designed through directed evolution, a powerful innovation for improving functionality of proteins. For example, in the case of MDNA11, fusion of our IL-2 super-agonist to albumin enhances the half-life of the drug allowing for extending dosing schedules from every 8 hours to every 2 weeks, while with MDNA55, fusion of an engineered IL-4 to a potent toxin empowers the Superkine with tumor-targeted killing capability.
These fusions are just the beginning of what Medicenna can create with its Superkine platform. Medicenna’s Superkines can be fused with a large variety of proteins, antibodies and even other Superkines to incorporate two synergistic mechanisms of action into one molecule: a BiSKIT.
Other possibilities include
- Fusing a Superkine to another Superkine allowing a break down of the defenses of a tumor with one Superkine, while simultaneously activating the cancer killing immune cells with another Superkine
- Fusing a Superkine to a cancer specific antibody allowing the two fused molecules to work in harmony by activating the immune system and enhancing the effect of the antibody at the tumor site.